Thursday, November 17, 2011
As pharmas increasingly look to offload early stage R&D
expenses, Cancer Research Technology Ltd., the
commercial arm of biomedical charity Cancer Research UK, has
seen more uptake of its partnered consortium model for commercializing the
discoveries of its stable of academic researchers. This year, Cancer Research
Technology has expanded its anchor collaboration with AstraZeneca plc by brokering two
more deals between the pharma and academic teams.
L. SciBX 4(45);
Published online Nov. 17, 2011
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Babraham Institute, Cambridge, U.K.
The Beatson Institute for Cancer Research, Glasgow, U.K.
Cambridge Research Institute, Cambridge, U.K.
Cancer Research Technology Ltd., London, U.K.
Cancer Research UK, London, U.K.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
Horizon Discovery Ltd., Cambridge, U.K.
Imperial College London, London, U.K.
London Research Institute, London, U.K.
Senectus Therapeutics Ltd., London, U.K.
University of Glasgow, Glasgow, U.K.
University of London, London, U.K.
University of Oxford, Oxford, U.K.